TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
Brief Summary: The purpose of this study is to determine if therapeutic modification of insulin resistance or oxidative stress leads to improvement in serum or histologic indicators of liver injury or quality of life.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin E | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): 3
B: Arm Label: Polypill; Type: EXPERIMENTAL; Interventions: Drug: Polypill | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Polypill; Assigned to Arm(s): Polypill
C: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Liraglutide-placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: OTHER; Name: Liraglutide-placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin E | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure
Brief Summary: The OPT-CHF (OxyPurinol Therapy for CHF) study is designed to demonstrate the efficacy and safety of oral oxypurinol vs. placebo in a randomized, double-blind, twenty-four week trial in 400 patients in up to 50 centers. Measures of clinical efficacy (NYHA class and Patient Global Assessment) as well as clinical outcomes (e.g., death, worsening heart failure, and hospitalization) will be assessed as a composite endpoint in this trial.


Options:
A: Arm Label: q2 wks; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: q4 wks; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: BIOLOGICAL; Name: pegloticase; Assigned to Arm(s): q2 wks, q4 wks
B: Arm Label: Febuxostat 40 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 80 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol 200 mg or 300 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 40 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 80 mg QD | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol 200 mg or 300 mg QD
C: Arm Label: q2 RCT; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: q4 RCT; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: Placebo in RCT; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Intervention Type: BIOLOGICAL; Name: pegloticase; Assigned to Arm(s): Placebo in RCT, q2 RCT, q4 RCT
D: Intervention Type: DRUG; Name: Oxypurinol; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without rituximab in treating patients with non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying four different combination chemotherapy regimens and rituximab to see how well they work compared to four different combination chemotherapy regimens alone in treating patients with non-Hodgkin's lymphoma.


Options:
A: Arm Label: JCAR017 1-dose schedule; Type: EXPERIMENTAL; Interventions: Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule | Arm Label: JCAR017 2-dose schedule (no longer accruing); Type: EXPERIMENTAL; Interventions: Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule | Intervention Type: BIOLOGICAL; Name: JCAR017 (lisocabtagene maraleucel) single-dose schedule; Assigned to Arm(s): JCAR017 1-dose schedule | Intervention Type: BIOLOGICAL; Name: JCAR017 (lisocabtagene maraleucel) 2-dose schedule; Assigned to Arm(s): JCAR017 2-dose schedule (no longer accruing)
B: Arm Label: Arm A: CHOP-21; Type: ACTIVE_COMPARATOR; Interventions: Drug: CHOP regimen | Arm Label: Arm B: CHOP-21 + Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Biological: rituximab, Drug: CHOP regimen | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): Arm B: CHOP-21 + Rituximab | Intervention Type: DRUG; Name: CHOP regimen; Assigned to Arm(s): Arm A: CHOP-21, Arm B: CHOP-21 + Rituximab
C: Arm Label: CD19-CART01; Type: EXPERIMENTAL; Interventions: Biological: CD19-CAR T cell | Intervention Type: BIOLOGICAL; Name: CD19-CAR T cell; Assigned to Arm(s): CD19-CART01
D: Intervention Type: BIOLOGICAL; Name: chimeric antigen receptor T cells; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without rituximab in treating patients with non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying four different combination chemotherapy regimens and rituximab to see how well they work compared to four different combination chemotherapy regimens alone in treating patients with non-Hodgkin's lymphoma.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm A: CHOP-21; Type: ACTIVE_COMPARATOR; Interventions: Drug: CHOP regimen | Arm Label: Arm B: CHOP-21 + Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Biological: rituximab, Drug: CHOP regimen | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): Arm B: CHOP-21 + Rituximab | Intervention Type: DRUG; Name: CHOP regimen; Assigned to Arm(s): Arm A: CHOP-21, Arm B: CHOP-21 + Rituximab
D: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.
Brief Summary: This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of symptoms.


Options:
A: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fondaparinux - UFH not indicated; Type: EXPERIMENTAL; Interventions: Drug: fondaparinux - UFH not indicated | Arm Label: Control - UFH not indicated; Type: PLACEBO_COMPARATOR; Interventions: Other: Control - UFH not indicated | Arm Label: Fondaparinux - UFH indicated; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux - UFH indicated | Arm Label: Control - unfractionated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Control - UFH | Intervention Type: DRUG; Name: fondaparinux - UFH not indicated; Assigned to Arm(s): Fondaparinux - UFH not indicated | Intervention Type: OTHER; Name: Control - UFH not indicated; Assigned to Arm(s): Control - UFH not indicated | Intervention Type: DRUG; Name: Fondaparinux - UFH indicated; Assigned to Arm(s): Fondaparinux - UFH indicated | Intervention Type: DRUG; Name: Control - UFH; Assigned to Arm(s): Control - unfractionated heparin
D: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): Enoxaparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated Distal Symmetrical Polyneuropathy
Brief Summary: The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is effective in treating painful HIV-associated neuropathy.


Options:
A: Intervention Type: DRUG; Name: NGX-4010; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: NGX-4010; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
D: Intervention Type: DRUG; Name: Capsaicin Dermal Patch; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of the Burch Modified Tanagho and Autologous Fascia Sling Procedures for Women With Predominantly Stress Urinary Incontinence
Brief Summary: The primary aim of this clinical trial is to compare the treatment success for two surgical procedures that are frequently used and have similar cure rates, yet have not been compared directly to each other in a large, rigorously conducted randomized trial. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and need for other treatment(s)after surgery. Follow-up will be a minimum of two years and up to four years.


Options:
A: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Darifenacin | Arm Label: 2; Type: OTHER; Interventions: Drug: Darifenacin, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: tolterodine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: bladder training | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor muscle training | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor rehabilitation | Intervention Type: PROCEDURE; Name: tolterodine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: bladder training; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: pelvic floor muscle training; Assigned to Arm(s): 3 | Intervention Type: PROCEDURE; Name: pelvic floor rehabilitation; Assigned to Arm(s): 4
D: Arm Label: Group Bladder Training; Type: EXPERIMENTAL; Interventions: Other: Bladder Training | Arm Label: Group TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: TMAP | Arm Label: Group Bladder Training + TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Bladder Training + TMAP | Intervention Type: OTHER; Name: Bladder Training; Assigned to Arm(s): Group Bladder Training | Intervention Type: OTHER; Name: TMAP; Assigned to Arm(s): Group TMAP | Intervention Type: OTHER; Name: Bladder Training + TMAP; Assigned to Arm(s): Group Bladder Training + TMAP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of the Burch Modified Tanagho and Autologous Fascia Sling Procedures for Women With Predominantly Stress Urinary Incontinence
Brief Summary: The primary aim of this clinical trial is to compare the treatment success for two surgical procedures that are frequently used and have similar cure rates, yet have not been compared directly to each other in a large, rigorously conducted randomized trial. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and need for other treatment(s)after surgery. Follow-up will be a minimum of two years and up to four years.


Options:
A: Arm Label: Ajust sling; Type: EXPERIMENTAL; Interventions: Procedure: Ajust system, Procedure: TVT/TVT-O | Arm Label: TVT/TVT-O, polypropylne slings; Type: EXPERIMENTAL; Interventions: Procedure: Ajust system, Procedure: TVT/TVT-O | Intervention Type: PROCEDURE; Name: Ajust system; Assigned to Arm(s): Ajust sling, TVT/TVT-O, polypropylne slings | Intervention Type: PROCEDURE; Name: TVT/TVT-O; Assigned to Arm(s): Ajust sling, TVT/TVT-O, polypropylne slings
B: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
C: Arm Label: BMI <30; Type: N/A; Interventions: N/A | Arm Label: BMI 30-39; Type: N/A; Interventions: N/A | Arm Label: BMI >40; Type: N/A; Interventions: N/A
D: Arm Label: Nitrofurantoin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Nitrofurantoin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of the Burch Modified Tanagho and Autologous Fascia Sling Procedures for Women With Predominantly Stress Urinary Incontinence
Brief Summary: The primary aim of this clinical trial is to compare the treatment success for two surgical procedures that are frequently used and have similar cure rates, yet have not been compared directly to each other in a large, rigorously conducted randomized trial. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and need for other treatment(s)after surgery. Follow-up will be a minimum of two years and up to four years.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: retropubic mid-urethral sling (TVT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transobturator mid-urethral sling (TVT-O and the Monarc) | Intervention Type: PROCEDURE; Name: retropubic mid-urethral sling (TVT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: transobturator mid-urethral sling (TVT-O and the Monarc); Assigned to Arm(s): 2
B: Arm Label: Abdominal Sacral Colpopexy with no Burch colposuspension; Type: N/A; Interventions: N/A | Arm Label: Abdominal Sacral Colpopexy with Burch Colposuspension; Type: N/A; Interventions: N/A
C: Arm Label: Abdominal Sacral Colpopexy with no Burch colposuspension; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Abdominal Sacral Colpopexy with Burch Colposuspension; Type: EXPERIMENTAL; Interventions: Procedure: Burch urethropexy at time of sacrocolpopexy | Intervention Type: PROCEDURE; Name: Burch urethropexy at time of sacrocolpopexy; Assigned to Arm(s): Abdominal Sacral Colpopexy with Burch Colposuspension
D: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of the Burch Modified Tanagho and Autologous Fascia Sling Procedures for Women With Predominantly Stress Urinary Incontinence
Brief Summary: The primary aim of this clinical trial is to compare the treatment success for two surgical procedures that are frequently used and have similar cure rates, yet have not been compared directly to each other in a large, rigorously conducted randomized trial. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and need for other treatment(s)after surgery. Follow-up will be a minimum of two years and up to four years.


Options:
A: Arm Label: Autologous Fascial Sling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Autologous fascial sling | Arm Label: TVT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: TVT | Arm Label: Pelvicol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Pelvicol | Intervention Type: PROCEDURE; Name: Autologous fascial sling; Assigned to Arm(s): Autologous Fascial Sling | Intervention Type: PROCEDURE; Name: TVT; Assigned to Arm(s): TVT | Intervention Type: PROCEDURE; Name: Pelvicol; Assigned to Arm(s): Pelvicol
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: retropubic mid-urethral sling (TVT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transobturator mid-urethral sling (TVT-O and the Monarc) | Intervention Type: PROCEDURE; Name: retropubic mid-urethral sling (TVT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: transobturator mid-urethral sling (TVT-O and the Monarc); Assigned to Arm(s): 2
C: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
D: Arm Label: 2; Type: N/A; Interventions: Procedure: AFS and TVT | Intervention Type: PROCEDURE; Name: AFS and TVT; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Brief Summary: The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.


Options:
A: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2
D: Arm Label: High Dose Multivitamin; Type: EXPERIMENTAL; Interventions: Drug: High Dose Multivitamin | Arm Label: Low Dose Multivitamin; Type: ACTIVE_COMPARATOR; Interventions: Device: Low Dose Multivitamin | Intervention Type: DRUG; Name: High Dose Multivitamin; Assigned to Arm(s): High Dose Multivitamin | Intervention Type: DEVICE; Name: Low Dose Multivitamin; Assigned to Arm(s): Low Dose Multivitamin

Answer: D